NEWS

Position:

Corporate News

Media coverage

Corporate Announcement

Shijiazhuang Sihua Pharmaceutical Group’s Guangxiang Pharmaceutical and Guolong Pharmaceutical have been recognized as demonstration enterprises for specialization, refinement, uniqueness, and innovation in Hebei Province.

Category:

Corporate Announcement

Time:2022-01-22

【概要描述】 Recently, the Department of Industry and Information Technology of Hebei Province announced the fourth batch of “Specialized, Fine, Distinctive, and Innovative” demonstration enterprises in Hebei Province. Shijiazhuang Sihua Pharmaceutical Group’s Hebei Guangxiang Pharmaceutical Co., Ltd. and Hebei Guolong Pharmaceutical Co., Ltd. were both recognized as Hebei Province’s “Specialized, Fine, Distinctive, and Innovative” demonstration enterprises.

At the start of the new year, good news has been pouring in. Recently, the Department of Industry and Information Technology of Hebei Province announced the fourth batch of “Specialized, Fine, Distinctive, and Innovative” demonstration enterprises in Hebei Province. Shijiazhuang Siyao Group Hebei Guangxiang Pharmaceutical Co., Ltd. and Hebei Guolong Pharmaceutical Co., Ltd. have both been recognized as Hebei Province’s “Specialized, Fine, Distinctive, and Innovative” demonstration enterprises.

It is reported that “specialized, refined, distinctive, and innovative” demonstration enterprises are those that possess the characteristics of “professionalism, refinement, distinctiveness, and novelty.” These enterprises are required to rank among the top in their niche markets in terms of economic performance, degree of specialization, innovation capability, and operational management. They represent cutting-edge innovation capabilities within their industries and hold core technological expertise in key areas. This award involves a comprehensive assessment and professional review of enterprises across multiple dimensions, including business performance indicators, R&D investment, innovation capacity, market share, and intellectual property rights.

Guangxiang Pharmaceutical Group, based on bulk active pharmaceutical ingredients such as caffeine, metronidazole, theophylline, aminophylline, and nifedipine, is a large-scale domestic industrial base for the production, R&D, and export of dozens of high-value-added specialty APIs—including abidol, pentoxifylline, agatocomban, rosuvastatin calcium, and pitavastatin calcium—while steadily enhancing its market influence. Guangxiang Pharmaceutical has established innovative R&D platforms for APIs in categories including anti-infectives, psychotropic drugs, respiratory system medications, and diabetes treatments. The company has successively collaborated with research institutions such as Tsinghua University and Tianjin University, creating an independent innovation system centered on industry-academia-research-application integration, technological platform development, and new product R&D, thereby laying a solid foundation for achieving product innovation and development. Guangxiang Pharmaceutical regards intelligentization and digitalization as crucial tools for improving production efficiency and product quality. It continuously introduces advanced international technologies as well as intelligent and digitally-enabled equipment, pioneering a new path of “digital transformation and upgrading” in the manufacturing industry among its peers. At the same time, benchmarking against international advanced standards, Guangxiang Pharmaceutical has been the first in the industry to adopt cutting-edge, widely applicable technologies such as high-temperature wet oxidation for COD reduction, MVR desalination, ozone catalytic oxidation, and biochemical treatment, thus driving enterprise growth and promoting technological advancement across the industry. The company has been recognized as a High-Tech Enterprise, Hebei Province Enterprise Technology Center, Hebei Province Technology Innovation Center, Hebei Province Micro-Reaction Continuous Synthesis API Engineering Research Center, Postdoctoral Research Workstation, Hebei Province Science and Technology-based Small and Medium-sized Enterprises, Hebei Province Specialized, Fine, and New SMEs, Hebei Province Industrial Enterprise R&D Institution (Grade A), and Hebei Province Green Factory.

Guolong Pharmaceutical Group has translated its innovative development philosophy into strategic actions, continuously deepening supply-side reform and optimizing its production and sales structure. Relying on technological innovation, product innovation, and business model innovation, as well as advanced equipment, cutting-edge technology, and outstanding management, the group has embarked on a path of innovative, green, and high-quality development. Guided by high-quality development, the group integrates its own strengths with those of research institutes and other institutions, tackling key technological challenges, resolving critical issues in product manufacturing processes, breaking through technological bottlenecks in industrial development, and steadily enhancing its independent R&D capabilities and the spillover effects of its scientific and technological achievements. This has enabled the company to achieve refined, standardized, and scientific development. The company’s finely crafted, serialized, and high-end active pharmaceutical ingredient (API) products have garnered widespread attention and recognition from both the industry and society. Its flagship products, including azithromycin, hydroxyethyl starch 40, and 130/0.4, rank among the top sellers in the domestic market. The company has successively been recognized as a High-Tech Enterprise, an A-level R&D institution among industrial enterprises in Hebei Province, a science-and-technology-based SME in Hebei Province, a specialized, refined, distinctive, and innovative SME in Hebei Province, and a Demonstration Enterprise for Technological Innovation in Hebei Province.

Relevant officials from the group stated that they will continue to deepen their expertise in the specialty API sector, leveraging the momentum of the country’s ongoing efforts to strengthen support and guidance for specialized, sophisticated, and innovative enterprises, as well as its policy of setting exemplary models. Upholding a development philosophy centered on innovation and adaptation, they will remain committed to the “specialized, sophisticated, and innovative” growth path, thereby better harnessing the enterprise’s role as a leading example and driving force.

Keywords:

Great news! Three products developed by Shijiazhuang No.4 Pharmaceutical—moxifloxacin hydrochloride eye drops, levofloxacin sodium chloride injection, and ipratropium bromide raw material—have been approved one after another by the Group’s Guangxiang Pharmaceutical.

Four employees from Guangxiang Pharmaceutical, a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, have been selected for the Provincial List of Innovative Talents in Science and Technology-based SMEs.